» Articles » PMID: 12752467

A Retrospective Analysis of Hippocampal Pathology in Human Temporal Lobe Epilepsy: Evidence for Distinctive Patient Subcategories

Overview
Journal Epilepsia
Specialty Neurology
Date 2003 May 20
PMID 12752467
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study is a retrospective analysis of the pathology of the hippocampus from patients with medically intractable temporal lobe epilepsy. We attempted to relate neuronal density, immunohistochemistry, electrophysiologic data, and surgical outcome.

Methods: Immunostaining patterns for neuropeptide Y, somatostatin, substance P, and dynorphin defined the immunohistochemical characteristics of the hippocampi. Neuronal densities were determined by microscopic cell counts. Sharp electrode recordings from dentate granule cells determined measures of inhibition and excitation.

Results: Patient hippocampi without evidence of sclerosis generally resembled autopsy controls on the basis of neuronal densities of hippocampal subfields and patterns of immunostaining. The nonsclerotic hippocampi were divisible into two subgroups on the basis of neuronal density correlations between hippocampal subfields, the excitability of dentate granule cells, etiology, and surgical outcome. Hippocampi with sclerosis were divisible into those with significant neuronal loss confined to area CA1 and those with neuronal loss throughout the hippocampus and dentate gyrus. In the former, the dentate gyrus resembled in morphology the nonsclerotic hippocampi but with slightly increased excitability of the dentate granule cells. The hippocampi with more extensive neuronal loss had changes in immunostaining patterns associated with the dentate gyrus, correlated with significant hyperexcitability of dentate granule cells. The surgical outcome, with the exception of one group, was good in approximately 70-90%.

Conclusions: Hippocampi from patients with intractable temporal lobe epilepsy can be assigned to several groups on the basis of pathophysiology. Different pathologies may represent differing causative mechanisms of intractable temporal lobe epilepsy and be predictive of surgical outcome.

Citing Articles

GABAergic Interneuron Cell Therapy for Drug-Resistant Epilepsy.

Chen J, Li Z, Wang Y, Chen L Neurosci Bull. 2024; 40(5):680-682.

PMID: 38491232 PMC: 11127856. DOI: 10.1007/s12264-024-01195-1.


Deep learning distinguishes connectomes from focal epilepsy patients and controls: feasibility and clinical implications.

Maher C, Tang Z, DSouza A, Cabezas M, Cai W, Barnett M Brain Commun. 2023; 5(6):fcad294.

PMID: 38025275 PMC: 10644981. DOI: 10.1093/braincomms/fcad294.


Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy.

Bershteyn M, Broer S, Parekh M, Maury Y, Havlicek S, Kriks S Cell Stem Cell. 2023; 30(10):1331-1350.e11.

PMID: 37802038 PMC: 10993865. DOI: 10.1016/j.stem.2023.08.013.


Cell therapy for neurological disorders: Progress towards an embryonic medial ganglionic eminence progenitor-based treatment.

Righes Marafiga J, Baraban S Front Neurosci. 2023; 17():1177678.

PMID: 37123353 PMC: 10140420. DOI: 10.3389/fnins.2023.1177678.


The inhibition of PGAM5 suppresses seizures in a kainate-induced epilepsy model mitophagy reduction.

Zhong F, Gan Y, Song J, Zhang W, Yuan S, Qin Z Front Mol Neurosci. 2023; 15:1047801.

PMID: 36618822 PMC: 9813404. DOI: 10.3389/fnmol.2022.1047801.